Acute otitis media (AOM) is inflammation of the fluid in the middle ear. AOM is the most common infection and mainly caused in children under the age of 7 years. According to an article published American Family Physician Journal in 2013, around 80% of children will have at least one episode of acute otitis media (AOM) before their school age. AOM is mainly caused by bacteria such as Streptococcus pneumoniae (strep) and Hemophilus influenzae (H. flu) and viruses. Bacteria account for 85% cases of AOM and viruses account for only 15%. AOM is mostly treated with antibiotics usually for 7–10 days and with some analgesic and anesthetic in order to the reduce pain.
Market Dynamics
Increasing prevalence of acute otitis media is expected to be a major driver for growth of the market. Acute otitis media is a very common disease and occurs mostly in children, therefore, increasing prevalence of this disease is expected to increase demand for treatment drugs, thereby positively affecting market growth. According to an article published in The Journal of Laryngology & Otology, in 2013, prevalence of otitis media subtypes is between 7.1–12.8%. Furthermore, recent launches and FDA approvals for new drugs for the treatment of acute otitis media is also expected to drive the market growth in the near future. For instance, in 2015, Otonomy, Inc. received U.S. Food and Drug Administration (FDA) approval for its OTIPRIO (ciprofloxacin otic suspension) indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement. In 2016, Otonomy, Inc. launched OTIPRIO in U.S. market.
Key features of the study:
- This report provides in-depth analysis of acute otitis media treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global acute otitis media treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
- Key companies covered as a part of this study include Pfizer, Inc., Eli Lilly and Company, Abbott Laboratories, GlaxoSmithKline plc., Bayer AG, Novartis AG, Pediapharm Inc., Sanofi S.A., and Bristol Myers Squibb Company.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global acute otitis media treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the acute otitis media treatment market
Detailed Segmentation:
- Global Acute Otitis Media Treatment Market, By Drug Type :
- Antibiotics
- Nonsteroidal anti-Inflammatory drug
- Analgesic
- Anaesthetic
- Global Acute Otitis Media Treatment Market, By Formulation:
- Global Acute Otitis Media Treatment Market, By Distribution Channel:
- Hospital
- Retail pharmacies
- Online pharmacies
- Global Acute Otitis Media Treatment Market, By Geography:
- North America
- By Drug Type :
- Antibiotics
- Nonsteroidal anti-Inflammatory drug
- Analgesic
- Anaesthetic
- By Formulation
- By Distribution Channel:
- Hospital
- Retail pharmacies
- Online pharmacies
- By Country:
- Europe
- By Drug Type :
- Antibiotics
- Nonsteroidal anti-Inflammatory drug
- Analgesic
- Anaesthetic
- By Formulation
- By Distribution Channel:
- Hospital
- Retail pharmacies
- Online pharmacies
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Type :
- Antibiotics
- Nonsteroidal anti-Inflammatory drug
- Analgesic
- Anaesthetic
- By Formulation
- By Distribution Channel:
- Hospital
- Retail pharmacies
- Online pharmacies
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Drug Type :
- Antibiotics
- Nonsteroidal anti-Inflammatory drug
- Analgesic
- Anaesthetic
- By Formulation
- By Distribution Channel:
- Hospital
- Retail pharmacies
- Online pharmacies
- By Country:
- Brazil
- Mexico
- Rest of Latin America
- Middle East
- By Drug Type :
- Antibiotics
- Nonsteroidal anti-Inflammatory drug
- Analgesic
- Anaesthetic
- By Formulation
- By Distribution Channel:
- Hospital
- Retail pharmacies
- Online pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Type :
- Antibiotics
- Nonsteroidal anti-Inflammatory drug
- Analgesic
- Anaesthetic
- By Formulation
- By Distribution Channel:
- Hospital
- Retail pharmacies
- Online pharmacies
- By Country:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- Pfizer, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Eli Lilly and Company
- Abbott Laboratories
- GlaxoSmithKline plc.
- Bayer AG
- Novartis AG
- Pediapharm Inc.
- Sanofi S.A.
- Bristol Myers Squibb Company
“*” marked represents similar segmentation in other categories in the respective section.
